Comparative Pharmacology
Head-to-head clinical analysis: E E S 200 versus ERYTHROCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E E S 200 versus ERYTHROCIN.
E.E.S. 200 vs ERYTHROCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It may also inhibit ribosomal assembly.
Erythromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It also exhibits anti-inflammatory and prokinetic effects via motilin receptor agonism.
400 mg orally every 6 hours as the ethylsuccinate salt. Maximum daily dose 4 g.
250-500 mg orally every 6 hours or 500 mg to 1 g intravenously every 6 hours.
None Documented
None Documented
Approximately 1.5-2 hours in adults with normal renal function; may be prolonged to 5-6 hours in severe renal impairment.
Terminal elimination half-life is approximately 1.5-2 hours in adults; may prolong to 4-6 hours in hepatic impairment or neonates.
Primarily hepatic metabolism and biliary excretion; approximately 5-15% of active drug excreted renally, with fecal elimination accounting for the majority of the remaining dose.
Primarily eliminated via biliary excretion as unchanged drug and metabolites; approximately 2-5% excreted renally as active drug, 15-20% as metabolites; up to 30% excreted in feces.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic